Mersana Therapeutics, Inc.
MRSN
$7.65
-$0.10-1.29%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 34.77M | 34.01M | 40.50M | 34.84M | 29.94M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 34.77M | 34.01M | 40.50M | 34.84M | 29.94M |
| Cost of Revenue | 71.65M | 72.68M | 73.02M | 72.23M | 87.96M |
| Gross Profit | -36.88M | -38.67M | -32.52M | -37.39M | -58.02M |
| SG&A Expenses | 35.09M | 38.18M | 40.81M | 42.06M | 45.09M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 106.74M | 110.85M | 113.83M | 114.29M | 133.05M |
| Operating Income | -71.97M | -76.85M | -73.34M | -79.45M | -103.11M |
| Income Before Tax | -73.62M | -73.59M | -68.77M | -74.20M | -104.77M |
| Income Tax Expenses | 418.00K | 418.00K | 418.00K | 418.00K | -- |
| Earnings from Continuing Operations | -74.04 | -74.01 | -69.19 | -74.62 | -104.77 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -74.04M | -74.01M | -69.19M | -74.62M | -104.77M |
| EBIT | -71.97M | -76.85M | -73.34M | -79.45M | -103.11M |
| EBITDA | -70.56M | -75.33M | -71.71M | -77.78M | -101.41M |
| EPS Basic | -14.92 | -15.00 | -14.13 | -15.32 | -21.62 |
| Normalized Basic EPS | -8.78 | -9.32 | -8.78 | -9.46 | -12.38 |
| EPS Diluted | -14.92 | -15.00 | -14.13 | -15.32 | -21.62 |
| Normalized Diluted EPS | -8.78 | -9.32 | -8.78 | -9.46 | -12.38 |
| Average Basic Shares Outstanding | 19.82M | 19.73M | 19.61M | 19.49M | 19.40M |
| Average Diluted Shares Outstanding | 19.82M | 19.73M | 19.61M | 19.49M | 19.40M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |